Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 4,343 | 378 | 3,958 |
| Samples | 959 | 121 | 833 |
| Peptides | 451 | 67 | 405 |
Function
CDC27 · Cell division cycle 27
The protein encoded by this gene shares strong similarity with Saccharomyces cerevisiae protein Cdc27, and the gene product of Schizosaccharomyces pombe nuc 2. This protein is a component of the anaphase-promoting complex (APC), which is composed of eight protein subunits and is highly conserved in eukaryotic cells. This complex catalyzes the formation of cyclin B-ubiquitin conjugate, which is responsible for the ubiquitin-mediated proteolysis of B-type cyclins. The protein encoded by this gene and three other members of the APC complex contain tetratricopeptide (TPR) repeats, which are important for protein-protein interactions. This protein was shown to interact with mitotic checkpoint proteins including Mad2, p55CDC and BUBR1, and it may thus be involved in controlling the timing of mitosis. Alternative splicing of this gene results in multiple transcript variants. Related pseudogenes have been identified on chromosomes 2, 22 and Y. [provided by RefSeq, May 2014].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 425 amino-acid changes on canonical ENST00000066544 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CDC27 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CDC27 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 12/133 9% |
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 79/1592 5% |
| Non-Small Cell Lung Carcinoma | 35/304 12% | 43/1390 3% |
| Endometrial Carcinoma | 3/42 7% | 26/612 4% |
| Bladder Carcinoma | 2/58 3% | 40/956 4% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Colorectal Carcinoma | 9/143 6% | 93/3239 3% |
| Squamous Cell Lung Carcinoma | 7/57 12% | 19/810 2% |
| Cervical Carcinoma | 1/35 3% | 12/422 3% |
| Melanoma | 6/210 3% | 52/1899 3% |
| Other Solid Cancers | 2/94 2% | 41/1515 3% |
| Adrenocortical Carcinoma | 0/3 0% | 3/112 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Osteosarcoma | 0/45 0% | 5/166 3% |
| Gastric Carcinoma | 2/74 3% | 41/1809 2% |
| Non-Cancerous | 0/104 0% | 21/830 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Rhabdomyosarcoma | 1/33 3% | 3/171 2% |
| Other Sarcomas | 1/69 1% | 14/699 2% |
| Ovarian Carcinoma | 4/109 4% | 17/998 2% |
| Biliary Tract Carcinoma | 1/54 2% | 18/950 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 48/2534 2% |
| Burkitts Lymphoma | 4/32 12% | 0/196 0% |
| Hepatocellular Carcinoma | 1/46 2% | 38/2210 2% |
| Meningioma | 0/3 0% | 4/252 2% |
| Germ Cell Tumour | 0/25 0% | 3/169 2% |
| Neuroendocrine Tumour | 6/154 4% | 5/577 1% |
| Head and Neck Carcinoma | 3/85 4% | 19/1574 1% |
Mutation Distribution
Where CDC27 is mutated · all tissues, split by cell line vs tissue
How many mutations in CDC27 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 4,343 mutations in CDC27
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|